Cargando…
Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?
Pancreatic ductal adenocarcinoma is a highly aggressive disease, and medical as well as surgical therapeutic options are limited. This article reviews stage dependent treatment options, with a special focus on the current controversy of perioperative treatment regimens in initially borderline resect...
Autores principales: | Nitsche, Ulrich, Kong, Bo, Balmert, Alexander, Friess, Helmut, Kleeff, Jörg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234154/ https://www.ncbi.nlm.nih.gov/pubmed/28144084 http://dx.doi.org/10.4103/0971-5851.195731 |
Ejemplares similares
-
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
por: Gillen, Sonja, et al.
Publicado: (2010) -
Palliative Interventional and Surgical Therapy for Unresectable Pancreatic Cancer
por: Assfalg, Volker, et al.
Publicado: (2011) -
The evidence based dilemma of intraperitoneal drainage for pancreatic resection – a systematic review and meta-analysis
por: Nitsche, Ulrich, et al.
Publicado: (2014) -
Editorial: Perioperative optimization of patients undergoing pancreatic surgery
por: Kleeff, Jorg, et al.
Publicado: (2023) -
Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer?
por: Kleeff, Jörg, et al.
Publicado: (2019)